Additionally, PCSK9 inhibitors also demonstrate good efficacy and tolerability even in patients who are intolerant to statins, effectively lowering LDL-C levels without increasing the risk of new-onset diabetes. This evidence concerns the gene PCSK9 and diabetes mellitus.